Phyton Biotech, Inc. Receives CEP for Docetaxel API

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

VANCOUVER, Canada--(BUSINESS WIRE)--Phyton Biotech, a global supplier of high quality paclitaxel and docetaxel API, has been granted a Certificate of suitability to European Pharmacopeia (CEP) by the European Directorate for the Quality of Medicines and HealthCare (EDQM) for its docetaxel anhydrous active pharmaceutical ingredient (API). Phyton is the first North American or European based contract API supplier to be granted a CEP for docetaxel. Importantly, Phyton’s docetaxel API is not subject to the current worldwide shortage of 10-deacetylbaccatin (10-DAB) starting material because it uses paclitaxel from its own plant cell fermentation facility as its starting material.

Help employers find you! Check out all the jobs and post your resume.

Back to news